Targeting HLA-E and NKG2A in solid tumors to overcome resistance to cancer immunotherapies

Dr. Horowitz’s research focuses on human Natural Killer (NK) cells and CD8 T cells and their functional roles in microbial infections and cancer, autoimmunity, pregnancy and in transplantation. His analyses are designed to identify specific subsets of NK and CD8 T cells with enhanced immunotherapeutic (or pathogenic) potential, as well as to identify pathways regulating NK cell function that can be perturbed for therapeutic benefit. To achieve this goal, Dr. Horowitz’s lab uses an array of cutting-edge technologies, including mass cytometry (CyTOF), multiplexed in situ imaging, Olink proteomics, and single-cell and Spatial RNA sequencing along with genomic data on HLA class I and KIR genes to profile NK and CD8 T cells with ultra-resolution. His lab has established relationships with surgical and medical oncologists to create a translational framework for exploiting NK cells to improve T cell targeted therapies. In his presentation, Dr. Horowitz will discuss his current research in human bladder and non-small-cell lung cancers